Table 2.
Demographic and baseline disease characteristics of the study population.
| Characteristic | Patients (N = 113) |
|---|---|
| Age (years) | |
| Median (range) | 75 (42–95) |
| Mean (SD) | 73.7 (9.8) |
| < 65, n (%) | 21 (18.6) |
| ≥ 65, n (%) | 92 (81.4) |
| 65–69, n (%) | 17 (15.0) |
| 70–79, n (%) | 39 (34.5) |
| 80–89, n (%) | 35 (31.0) |
| ≥ 90, n (%) | 1 (0.9) |
| Sex, n (%) | |
| Men | 91 (80.5) |
| Race, n (%) | |
| White | 91 (80.5) |
| Black | 7 (6.2) |
| Asian | 1 (0.9) |
| Other | 7 (6.2) |
| Missing | 7 (6.2) |
| Ethnicity, n (%) | |
| Hispanic | 4 (3.5) |
| Non-Hispanic | 81 (71.7) |
| Unknown | 28 (24.8) |
| NMIBC tumor types, n (%) | |
| CIS alone | 58 (51.3) |
| NMIBC, unspecified | 36 (31.9) |
| CIS and papillary | 12 (10.6) |
| Papillary alone | 7 (6.2) |
| Time since diagnosis of bladder cancer (months) | |
| Median (range) | 31 (1–140) |
| Mean (SD) | 41 (30) |
| Prior treatment | |
| Intravesical immunotherapy (no. courses)$ | |
| Median (range)‡ | 2 (0–20) |
| Mean (SD) ‡ | 3.5 (4.3) |
| Intravesical chemotherapy (no. courses) | |
| Median (range) ‡ | 0 (0–15) |
| Mean (SD) ‡ | 0.7 (1.8) |
| Transurethral resection of the bladder tumor (no. procedures) | |
| Median (range) | 2 (0–13) |
| Mean (SD) | 2.5 (2.4) |
| Fulguration (no. procedures) | |
| Median (range) | 0 (0–15) |
| Mean (SD) | 1.1 (2.0) |
*
At the time of the first valrubicin instillation. $Includes bacillus Calmette–Guérin and unspecified immunotherapy. ‡Courses could have included up to six weekly instillations, but patient medical records did include cases in which fewer instillations or maintenance doses were received. In the review of patient medical records, courses were defined as a separation in time of more than several weeks after multiple weekly instillations.
CIS, carcinoma in situ; NMIBC, nonmuscle-invasive bladder cancer; SD, standard deviation.